Company intelligence / Profile preview

FyoniBio GmbH

Ownership: Private
Development stage: Other

Overview

FyoniBio does not have its own clinical pipeline but provides ISO 9001-certified contract development services including cell line engineering, process development, analytical characterization, bioassay development, and clinical sample analysis to pharma and biotech clients. Its scientists have supported programs that reached late-stage clinical trials.

Therapeutic areas: Other
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodiesRecombinant proteinsBiosimilars
Industry: Contract Manufacturing Organization

Partnerships

Strike Pharma ABGlycotope GmbHOther pharma/biotech companies (CDMO/CDO provider)

Beyond the preview

Go deeper on FyoniBio GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FyoniBio GmbH.

Explore the full profile